Frequency of skeletal-related events and associated healthcare resource use and costs in US patients with multiple myeloma

References

• Theriault RL, Theriault RL. Biology of bone metastases. Cancer Control 2012;19:92-101
   PubMed Web of Science ®Google Scholar
• Polascik TJ. Bisphosphonates in oncology: evidence for the prevention of skeletal events in patients with bone metastases. Drug Des Devel Ther 2009;3:27-40
   PubMed Web of Science ®Google Scholar
• Coleman RE. Management of bone metastases. Oncologist 2000;5:463-70
   PubMedGoogle Scholar
• Carter JA, Ji X, Botteman MF. Clinical, economic and humanistic burdens of skeletal-related events associated with bone metastases. Expert Rev Pharmacoecon Outcomes Res 2013;13:483-96
   PubMed Web of Science ®Google Scholar
• Terpos E, Dimopoulos MA, Berenson J. Established role of bisphosphonate therapy for prevention of skeletal complications from myeloma bone disease. Crit Rev Oncol Hematol 2011;77(1 Suppl):S13-S23
   PubMed Web of Science ®Google Scholar
• Cancer Facts & Figures 2013. Atlanta: American Cancer Society, 2013. Available at: http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-036845.pdf [Last accessed 26 August 2015]
   Google Scholar
• Terpos E, Morgan G, Dimopoulos MA, et al. International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease. J Clin Oncol 2013;31:2347-57
   PubMed Web of Science ®Google Scholar
• Berenson JR, Lichtenstein A, Porter L, et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol 1998;16:593-602
   PubMed Web of Science ®Google Scholar
• Berenson JR, Lichtenstein A, Porter L, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med 1996;334:488-93
   PubMed Web of Science ®Google Scholar
• Berenson JR, Rosen LS, Howell A, et al. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer 2001;91:1191-200
   PubMed Web of Science ®Google Scholar
• Gimsing P, Carlson K, Turesson I, et al. Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial. Lancet Oncol 2010;11:973-82
   PubMed Web of Science ®Google Scholar
• Rosen LS, Gordon D, Kaminski M, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 2001;7:377-87
   PubMed Web of Science ®Google Scholar
• Rosen LS, Gordon D, Kaminski M, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 2003;98:1735-44
   PubMed Web of Science ®Google Scholar
• Zometa, Prescribing Information. East Hanover: Novartis, 2012. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021223s022lbl.pdf [Last accessed 11 March 2014].
   Google Scholar
• Aredia, Prescribing Information. East Hanover: Novartis, 2010. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020036s039lbl.pdf[Last accessed 11 March 2014].
   Google Scholar
• Anderson KC, Alsina M, Atanackovic D, et al. Multiple myeloma, version 2.2016. J Natl Compr Canc Netw 2015;13:1398-435.
   PubMed Web of Science ®Google Scholar
• Theriault RL, Lipton A, Hortobagyi GN, et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol 1999;17:846-54
   PubMed Web of Science ®Google Scholar
• Mahmood A, Ghazal H, Fink MG, et al. Health-resource utilization attributable to skeletal-related events in patients with advanced cancers associated with bone metastases: results of the US cohort from a multicenter observational study. Community Oncology 2012;9:148-57
   Google Scholar
• Lage MJ, Barber BL, Harrison DJ, et al. The cost of treating skeletal-related events in patients with prostate cancer. Am J Manag Care 2008;14:317-22
   PubMed Web of Science ®Google Scholar
• Barlev A, Song X, Ivanov B, et al. Payer costs for inpatient treatment of pathologic fracture, surgery to bone, and spinal cord compression among patients with multiple myeloma or bone metastasis secondary to prostate or breast cancer. J Manag Care Pharm 2010;16:693-702
   PubMed Web of Science ®Google Scholar
• Delea T, McKiernan J, Brandman J, et al. Retrospective study of the effect of skeletal complications on total medical care costs in patients with bone metastases of breast cancer seen in typical clinical practice. J Support Oncol 2006;4:341-7
   PubMedGoogle Scholar
• Hagiwara M, Delea TE, Chung K. Healthcare costs associated with skeletal-related events in breast cancer patients with bone metastases. J Med Econ 2014;17:223-30
   PubMedGoogle Scholar
• Bahl A, Hoefeler H, Duran I, et al. Health Resource Utilization Associated with skeletal-related events in patients with advanced prostate cancer: a European subgroup analysis from an observational, multinational study. J Clin Med 2014;3:883-96
   PubMedGoogle Scholar
• Lorusso V, Duran I, Garzon-Rodriguez C, et al. Health resource utilisation associated with skeletal-related events in European patients with lung cancer: Alpha subgroup analysis from a prospective multinational study. Mol Clin Oncol 2014;2:701-8
   PubMedGoogle Scholar
• Luftner D, Lorusso V, Duran I, et al. Health resource utilization associated with skeletal-related events in patients with advanced breast cancer: results from a prospective, multinational observational study. SpringerPlus 2014;3:328-37.
   PubMed Web of Science ®Google Scholar
• Duran I, Garzon C, Sanchez A, et al. Cost analysis of skeletal-related events in Spanish patients with bone metastases from solid tumours. Clin Transl Oncol 2014;16:322-9
   PubMed Web of Science ®Google Scholar
• Hoefeler H, Duran I, Hechmati G, et al. Health resource utilization associated with skeletal-related events in patients with bone metastases: Results from a multinational retrospective - prospective observational study - a cohort from 4 European countries. J Bone Oncol 2014;3:40-8
   PubMed Web of Science ®Google Scholar
• Rizzo M, Xu Y, Panjabi S, et al. A systematic literature review of the economic burden in multiple myeloma. ISPOR 17th Annual European Congress. November 8-12, 2014; Amsterdam, The Netherlands.
   Google Scholar
• Groot MT, Huijgens PC, Wijermans PJ, et al. Costs of multiple myeloma and associated skeletal-related events in The Netherlands. Expert Rev Pharmacoecon Outcomes Res 2004;4:565-72
   PubMedGoogle Scholar
• Schulman KL, Kohles J. Economic burden of metastatic bone disease in the U.S. Cancer 2007;109:2334-42
   PubMed Web of Science ®Google Scholar
• Ashcroft J, Timothy B, Smith A, et al. Skeletal-related events in myeloma: A population-based study. 2013 American Society of Hematology (ASH) Annual Meeting and Exposition. December 7-10, 2013; New Orleans, LA.
   Google Scholar
• Truven Health Analytics. 2014 Truven Health Analytics MarketScan Publication and Trademark Guidelines; Ann Arbor, 2014.
   Google Scholar
• Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-19
   PubMed Web of Science ®Google Scholar
• Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res 2011;46:399-424
   PubMed Web of Science ®Google Scholar
• Efron B, Tibshirani R. Bootstrap methods for standard errors, confidence intervals, and other measures of statistical accuracy. Statist Sci 1986;1:54-77
   Google Scholar
• Anderson KC, Alsina M, Bensinger W, et al. NCCN clinical practice guidelines in oncology: multiple myeloma. J Natl Compr Canc Netw 2009;7:908-42
   PubMed Web of Science ®Google Scholar
• Berenson JR, Hillner BE, Kyle RA, et al. American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncol 2002;20:3719-36
   PubMed Web of Science ®Google Scholar
• Lacy MQ, Dispenzieri A, Gertz MA, et al. Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc 2006;81:1047-53
   PubMed Web of Science ®Google Scholar
• Durie BG. Use of bisphosphonates in multiple myeloma: IMWG response to Mayo Clinic consensus statement. Mayo Clin Proc 2007;82:516-17
   PubMed Web of Science ®Google Scholar
• Hortobagyi GN, Theriault RL, Lipton A, et al. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol 1998;16:2038-44
   PubMed Web of Science ®Google Scholar
• Chandran A, Bonafede MK, Nigam S, et al. Adherence to insulin pen therapy is associated with reduction in healthcare costs among patients with type 2 diabetes mellitus. Am Health Drug Benefits 2015;8:148-58
   PubMed Web of Science ®Google Scholar
• Bonafede MM, Kalra VB, Miller JD, et al. Value analysis of digital breast tomosynthesis for breast cancer screening in a commercially-insured US population. Clinicoecon Outcomes Res 2015;7:53-63
   PubMedGoogle Scholar
• David G, Gill M, Gunnarsson C, et al. Switching from multiple daily injections to CSII pump therapy: insulin expenditures in type 2 diabetes. Am J Manag Care 2014;20:e490-7
   PubMed Web of Science ®Google Scholar
• Cappell KA, Shreay S, Cao Z, et al. Red blood cell (RBC) transfusion rates among US chronic dialysis patients during changes to Medicare end-stage renal disease (ESRD) reimbursement systems and erythropoiesis stimulating agent (ESA) labels. BMC Nephrol 2014;15:116
   PubMed Web of Science ®Google Scholar
• Mannino DM, Higuchi K, Yu TC, et al. Economic burden of COPD in the presence of comorbidities. Chest 2015;148:138-50
   PubMed Web of Science ®Google Scholar
• Bonafede MM, Johnson BH, Watson C. Health care-resource utilization before and after natalizumab initiation in multiple sclerosis patients in the US. Clinicoecon Outcomes Res 2013;6:11-20
   PubMedGoogle Scholar
• SEER Stat Fact Sheets: Myeloma. Surveillance, Epidemiology, and End Results Program. Bethesda: National Cancer Institute, 2015. Available at: http://seer.cancer.gov/statfacts/html/mulmy.html [Last accessed 11 March 2014]
   Google Scholar
• Teitelbaum A, Ba-Mancini A, Huang H, et al. Health care costs and resource utilization, including patient burden, associated with novel-agent-based treatment versus other therapies for multiple myeloma: findings using real-world claims data. Oncologist 2013;18:37-45
   PubMed Web of Science ®Google Scholar